APA
Becker A., Kreitmann L., Triffaut-Fillit C., Valour F., Mabrut E., Forestier E., Lesens O., Cazorla C., Descamps S., Boyer B., Chidiac C., Lustig S., Montbarbon E., Batailler C. & Ferry T. (2020). Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to. : Journal of bone and joint infection.
Chicago
Becker A, Kreitmann L, Triffaut-Fillit C, Valour F, Mabrut E, Forestier E, Lesens O, Cazorla C, Descamps S, Boyer B, Chidiac C, Lustig S, Montbarbon E, Batailler C and Ferry T. 2020. Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to. : Journal of bone and joint infection.
Harvard
Becker A., Kreitmann L., Triffaut-Fillit C., Valour F., Mabrut E., Forestier E., Lesens O., Cazorla C., Descamps S., Boyer B., Chidiac C., Lustig S., Montbarbon E., Batailler C. and Ferry T. (2020). Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to. : Journal of bone and joint infection.
MLA
Becker A, Kreitmann L, Triffaut-Fillit C, Valour F, Mabrut E, Forestier E, Lesens O, Cazorla C, Descamps S, Boyer B, Chidiac C, Lustig S, Montbarbon E, Batailler C and Ferry T. Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to. : Journal of bone and joint infection. 2020.